Last update Aug. 6, 2017
Very Low Risk
A 14-amino acid synthetic peptide related to the endogenous guanylin peptide family.
Administered in moderate-severe constipation from irritable bowel syndrome and in idiopathic chronic constipation.
It acts locally in the intestine, without being absorbed (EMA 2016). It is metabolized in the intestine obtaining its main active metabolite, des-tyrosine. Both linaclotide and des-tyrosine are digested by intestinal enzymes and transformed into natural amino acids.
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic data (zero or negligible intestinal absorption with undetectable plasma levels and high molecular weight) make it very unlikely that significant amounts will pass to breast milk (EMA 2016).
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM